Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg

Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesity 
trial with liraglutide 3 mg 
BAGSVAERD, DENMARK -- (Marketwired) -- 05/23/13 --   Company
announcement No 39 2013: http://hugin.info/2013/R/1704259/563495.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Novo Nordisk A/S via Thomson Reuters ONE 
[HUG#1704259] 
Further information
Media:
Daniel Vamosi Martinussen
+45 3079 1879
dvmm@novonordisk.com 
Ken Inchausti (US)
+1 609 240 2919
kiau@novonordisk.com 
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
krop@novonordisk.com 
Frank Daniel Mersebach
+45 4442 0604
fdni@novonordisk.com 
Lars Borup Jacobsen
+45 3075 3479
lbpj@novonordisk.com 
Jannick Lindegaard (US)
+1 609 786 4575
jlis@novonordisk.com